A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

Clinical trial NCT02170727 · COMPLETED

Trial details

NCT number: NCT02170727
Sponsor: Bristol-Myers Squibb
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatitis C Virus

Start date: 2014-06-26
Primary completion: 2015-06-12
Enrollment: 199

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.